DCF Advisers LLC Takes Position in Corvus Pharmaceuticals, Inc. $CRVS

DCF Advisers LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 637,500 shares of the company’s stock, valued at approximately $9,524,000. Corvus Pharmaceuticals comprises approximately 1.7% of DCF Advisers LLC’s investment portfolio, making the stock its 6th largest holding.

A number of other hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its position in Corvus Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after purchasing an additional 748 shares in the last quarter. ProShare Advisors LLC grew its position in Corvus Pharmaceuticals by 7.7% during the 4th quarter. ProShare Advisors LLC now owns 13,764 shares of the company’s stock worth $106,000 after acquiring an additional 979 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Corvus Pharmaceuticals by 5.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company’s stock worth $263,000 after acquiring an additional 1,696 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Corvus Pharmaceuticals by 6.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Insider Buying and Selling

In other news, Director David Scott Moore purchased 21,700 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $11.53 per share, with a total value of $250,201.00. Following the purchase, the director directly owned 21,700 shares of the company’s stock, valued at $250,201. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 19.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on CRVS. Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Finally, Weiss Ratings raised shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.

Corvus Pharmaceuticals Trading Up 3.8%

NASDAQ CRVS opened at $15.40 on Thursday. Corvus Pharmaceuticals, Inc. has a 12 month low of $5.03 and a 12 month high of $26.95. The stock has a 50-day simple moving average of $13.95 and a 200 day simple moving average of $14.95. The company has a market capitalization of $1.30 billion, a PE ratio of -25.25 and a beta of 0.87.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 earnings per share for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.